<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05083754</url>
  </required_header>
  <id_info>
    <org_study_id>J21103</org_study_id>
    <nct_id>NCT05083754</nct_id>
  </id_info>
  <brief_title>Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma</brief_title>
  <official_title>A Randomized, Open-label Pilot Trial to Evaluate the Safety and Efficacy of Carmustine Wafer in Combination With Retifanlimab and Standard Radiation With or Without Temozolomide in Newly-Diagnosed Adult Subjects With Glioblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the safety and survival of carmustine wafers and&#xD;
      radiation and retifanlimab with or without temozolomide (TMZ) in newly-diagnosed adult&#xD;
      subjects with glioblastoma multiform after carmustine wafer placement.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">January 2027</completion_date>
  <primary_completion_date type="Anticipated">January 2026</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of combination retifanlimab and radiation with and without temozolomide as assessed by number of participants who experience adverse events</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Number of participants who experience grade 1 or higher adverse events, as defined by Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility of combination retifanlimab and radiation with and without temozolomide as assessed by number of participants who experience adverse events</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Number of participants who experience grade 1 or higher adverse events, as defined by Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) as determined by number of participants with dose limiting toxicities (DLT)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Maximum tolerated dose will be determined by the maximum dose at which the least number of participants experience dose-limiting toxicity. The dose limiting toxicity is defined using the Common Terminology Criteria for Adverse Events (CTCAE).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety as assessed by number of treatment-emergent adverse events in patients on combination refitanlimab and standard of care (SOC) with newly diagnosed glioblastoma after treatment with carmustine wafers</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Number of participants who experience grade 1 or higher adverse events, as defined by Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Proportion of participants who achieve progression free survival who are treated with retifanlimab with or without temozolomide after carmustine placement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>Upt to 2 years</time_frame>
    <description>Proportion of participants with measurable disease at baseline and have been re-evaluated after at least 1 cycle of therapy with observed reduction in tumor burden as defined by RECIST (Response evaluation criteria in solid tumors) and iRECIST criteria after 2 doses of nivolumab and ipilimumab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Proportion of participants who achieve survival with methylated or unmethylated methylguanine-DNA-methyltransferase (MGMT)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Tumor Response as assessed by immune markers in tumor and blood samples</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Analyses may include flow cytometry and immunohistochemistry</description>
  </other_outcome>
  <other_outcome>
    <measure>Biomarker assessment in tumor and blood samples</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Analyses may include, but not necessarily be limited to, the proportion of T, B, and NK cells, granulocytes, the proportion of memory and effector T cell subsets, and expression levels of PD-1, PD-L1, other B7 family members, ICOS, and Ki67.</description>
  </other_outcome>
  <other_outcome>
    <measure>Microsatellite instability (MSI) assessment</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Assess presence or absence of MSI</description>
  </other_outcome>
  <other_outcome>
    <measure>NK cell count</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>NK cell count in cells/mm^3</description>
  </other_outcome>
  <other_outcome>
    <measure>PD-1 cell</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>PD-1 cell count in cells/mm^3</description>
  </other_outcome>
  <other_outcome>
    <measure>T cell count</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>T cell count in cells/mm^3</description>
  </other_outcome>
  <other_outcome>
    <measure>B cell count</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>B cell count in cells/mm^3</description>
  </other_outcome>
  <other_outcome>
    <measure>PD L-1 count</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>PD L-1 cell count in cells/mm^3</description>
  </other_outcome>
  <other_outcome>
    <measure>ICOS count</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>ICOS cell count in cells/mm^3</description>
  </other_outcome>
  <other_outcome>
    <measure>CD4 cell count</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>CD4 cell count in cells/mm^3</description>
  </other_outcome>
  <other_outcome>
    <measure>CD8 cell count</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>CD8 cell count in cells/mm^3</description>
  </other_outcome>
  <other_outcome>
    <measure>Ki67 cell count</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Ki67 cell count in cells/mm^3</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <arm_group>
    <arm_group_label>Arm A- Retifanlimab and Radiation Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Retifanlimab and Radiation Therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B- Retifanlimab, Radiation Therapy and Temozolomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Retifanlimab, Radiation Therapy and Temozolomide.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C- Radiation Therapy and Temozolomide</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will receive Radiation Therapy and Temozolomide which is the Standard of Care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Retifanlimab</intervention_name>
    <description>Anti-PD-1 Therapy</description>
    <arm_group_label>Arm A- Retifanlimab and Radiation Therapy</arm_group_label>
    <arm_group_label>Arm B- Retifanlimab, Radiation Therapy and Temozolomide</arm_group_label>
    <other_name>INCMGA00012</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>Anti-PD-1 Therapy</description>
    <arm_group_label>Arm B- Retifanlimab, Radiation Therapy and Temozolomide</arm_group_label>
    <arm_group_label>Arm C- Radiation Therapy and Temozolomide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation Therapy</intervention_name>
    <description>Standard of Care</description>
    <arm_group_label>Arm A- Retifanlimab and Radiation Therapy</arm_group_label>
    <arm_group_label>Arm B- Retifanlimab, Radiation Therapy and Temozolomide</arm_group_label>
    <arm_group_label>Arm C- Radiation Therapy and Temozolomide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Newly-diagnosed adults with WHO (World Health Organization) Grade IV Glioblastoma or&#xD;
             gliosarcoma based on histopathological or molecular criteria who had carmustine wafers&#xD;
             placed at resection&#xD;
&#xD;
          -  No prior treatment for GBM other than surgical resection and carmustine wafer&#xD;
             placement (Patients who had a biopsy prior to resection are allowed)&#xD;
&#xD;
          -  Post-operative MRI or CT scan within 72 hours (preferably 24 hours) of surgical&#xD;
             resection&#xD;
&#xD;
          -  Substantial recovery from surgical resection&#xD;
&#xD;
          -  On a stable or decreasing dose of steroids&#xD;
&#xD;
          -  Karnofsky Performance Status of ≥ 60&#xD;
&#xD;
          -  Clinically appropriate for concomitant temozolomide plus radiation therapy (RT) based&#xD;
             on institutional guidelines&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  Ensure that pregnant or lactating females are not enrolled and that contraceptive&#xD;
             requirements are in accordance with applicable and recent requirements.&#xD;
&#xD;
          -  Men must agree to take appropriate precautions to avoid fathering children (with at&#xD;
             least 99% certainty) from screening through 180 days after the last dose of&#xD;
             retifanlimab&#xD;
&#xD;
          -  Must have normal organ and marrow function on routine laboratory tests&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document&#xD;
&#xD;
          -  Subjects must be willing and able to comply with scheduled visits, treatment schedule,&#xD;
             study procedures, and other requirements of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Recurrent glioblastoma (GBM) or progression of lower grade tumor&#xD;
&#xD;
          -  Central nervous system (CNS) hemorrhage of Grade &gt; 1 on baseline MRI scan, unless&#xD;
             subsequently documented to have resolved&#xD;
&#xD;
          -  Any known metastatic extracranial or leptomeningeal disease&#xD;
&#xD;
          -  Intent to use other anti-neoplastic medications/treatments including the Optune®&#xD;
             device&#xD;
&#xD;
          -  Any serious or uncontrolled medical disorder that, in the opinion of the investigator,&#xD;
             may increase the risk associated with study participation or study drug&#xD;
             administration, impair the ability of the subject to receive protocol therapy, or&#xD;
             interfere with the interpretation of study results&#xD;
&#xD;
          -  Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, anti-CTLA-4&#xD;
             antibody or any other antibody or drug specifically targeting T-cell co-stimulation or&#xD;
             immune checkpoint pathways&#xD;
&#xD;
          -  Active, known or suspected autoimmune disease, with the following exceptions: Subjects&#xD;
             with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin&#xD;
             disorders (such as vitiligo, psoriasis or alopecia) not requiring systemic treatment&#xD;
             (subjects with a history of flares requiring systemic treatment are excluded), or&#xD;
             other autoimmune conditions not expected to recur in the absence of an external&#xD;
             trigger are permitted to enroll&#xD;
&#xD;
          -  Subjects with history of life-threatening toxicity, including hypersensitivity&#xD;
             reaction, related to prior immunoglobulin treatment for another condition (except&#xD;
             those considered unlikely to re-occur, with written approval of study PI) or any other&#xD;
             study drug component&#xD;
&#xD;
          -  History or evidence upon physical/neurological examination of other central nervous&#xD;
             system condition (e.g., seizures, abscess) unrelated to cancer, unless adequately&#xD;
             controlled by medication or considered not potentially interfering with protocol&#xD;
             treatment&#xD;
&#xD;
          -  Surgical procedure &lt; 7 days prior to study treatment (No restriction for insertion of&#xD;
             a central venous access device)&#xD;
&#xD;
          -  Unable to swallow oral medication or any gastrointestinal disease or surgical&#xD;
             procedure that may seriously impact the absorption of temozolomide&#xD;
&#xD;
          -  Prior malignancy active within the previous 3 years except for locally curable cancers&#xD;
             that have been apparently cured, such as basal or squamous cell skin cancer, totally&#xD;
             excised melanoma of stage IIA or lower, low or intermediate-grade localized prostate&#xD;
             cancer (Gleason score ≤ 7), and curatively-treated carcinoma in situ of the cervix,&#xD;
             breast, or bladder.&#xD;
&#xD;
          -  Known history of any positive test for hepatitis B virus or hepatitis C virus&#xD;
             indicating acute or chronic infection, and/or detectable virus&#xD;
&#xD;
          -  Known history of positive test for human immunodeficiency virus (HIV) or known&#xD;
             acquired immunodeficiency syndrome (AIDS).&#xD;
&#xD;
          -  Evidence of interstitial lung disease, history of interstitial lung disease, or&#xD;
             active, noninfectious pneumonitis.&#xD;
&#xD;
          -  Palliative radiation therapy administered within 1 week of first dose of study&#xD;
             treatment or radiation therapy in the thoracic region that is &gt; 30 Gy within 6 months&#xD;
             of the first dose of study treatment. Note: Participants must have recovered from all&#xD;
             radiation-related toxicities (to Grade &gt;1 or baseline), not require corticosteroids&#xD;
             for this purpose, and not have had radiation pneumonitis.&#xD;
&#xD;
          -  Toxicity of prior therapy that has not recovered to ≤ Grade 1 or baseline (with the&#xD;
             exception of any grade of alopecia and anemia not requiring transfusion support).&#xD;
&#xD;
          -  Participants with specified abnormal laboratory values at screening&#xD;
&#xD;
          -  Active autoimmune disease requiring systemic immunosuppression in excess of&#xD;
             physiologic maintenance doses of corticosteroids (&gt; 10 mg/day of prednisone or&#xD;
             equivalent).&#xD;
&#xD;
               -  Physiologic corticosteroid replacement therapy at doses ≤ 10 mg/day of prednisone&#xD;
                  or equivalent for adrenal or pituitary insufficiency and in the absence of active&#xD;
                  autoimmune disease is permitted.&#xD;
&#xD;
               -  Participants with asthma that requires intermittent use of bronchodilators,&#xD;
                  inhaled steroids, or local steroid injections may participate.&#xD;
&#xD;
               -  Participants using topical, ocular, intra-articular, or intranasal steroids (with&#xD;
                  minimal systemic absorption) may participate.&#xD;
&#xD;
               -  Brief courses of corticosteroids for prophylaxis (e.g., contrast dye allergy) or&#xD;
                  study treatment-related standard premedication is permitted.&#xD;
&#xD;
          -  Has an active infection requiring systemic antibiotics or antifungal treatment&#xD;
&#xD;
          -  History of organ transplant, including allogeneic stem cell transplantation&#xD;
&#xD;
          -  Known allergy or hypersensitivity to any component of retifanlimab or formulation&#xD;
             components&#xD;
&#xD;
          -  Has received a live vaccine within 28 days of the planned start of study drug (Note:&#xD;
             Examples of live vaccines include but are not limited to measles, mumps, rubella,&#xD;
             chicken pox/zoster, yellow fever, rabies, Bacillus of Calmette and Guerin (BCG), and&#xD;
             typhoid vaccine. Inactivated seasonal influenza vaccines and COVID-19 vaccine(s) are&#xD;
             permitted and do not require a 4-week waiting period before starting study treatment;&#xD;
             however, intranasal influenza vaccines are live attenuated vaccines and are not&#xD;
             allowed.)&#xD;
&#xD;
          -  Patients who are taking Probiotic dietary supplements&#xD;
&#xD;
          -  Patients with uncontrolled intercurrent illness&#xD;
&#xD;
          -  Patients with psychiatric illness/social situations (e.g. prisoners/involuntarily&#xD;
             incarcerated individuals) that would limit compliance with study requirements&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lawrence Kleinberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lawrence Kleinberg, MD</last_name>
    <phone>410-614-2597</phone>
    <email>kleinla@jhmi.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stella Krawiec, MA</last_name>
    <phone>410-502-1962</phone>
    <email>skrawie1@jhmi.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Johns Hopkins Medical Institution</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Lawrence Kleinberg, MD</last_name>
      <phone>410-614-2597</phone>
      <email>kleinla@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Stella Krawiec, MA</last_name>
      <phone>410-502-1962</phone>
      <email>skrawie1@jhmi.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>October 6, 2021</study_first_submitted>
  <study_first_submitted_qc>October 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2021</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

